AB

AbClon Inc.

Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.

174900 | KO

Overview

Corporate Details

ISIN(s):
KR7174900001
LEI:
Country:
South Korea
Address:
서울특별시 구로구 디지털로 285 에이스트윈타워 1차 1401호, 구로구

Description

AbClon Inc. is a clinical-stage company focused on the research and development of antibody-based therapeutics. The company leverages three core proprietary platforms. The CAR-T platform develops personalized cell therapies for cancer patients by engineering a patient's own immune cells to target and destroy cancer cells, with a focus on blood cancers. The NEST (Novel Epitope Screening Technology) platform is designed to discover antibodies that target unique, previously unaddressed sites on disease proteins, enabling novel therapeutic effects. The AffiMab platform facilitates the development of bispecific antibodies that can simultaneously engage two different disease targets, aiming to maximize therapeutic efficacy in refractory diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-27 00:00
단일판매ㆍ공급계약체결
Korean 9.3 KB
2025-08-13 00:00
반기보고서 (2025.06)
Korean 1.1 MB
2025-08-11 00:00
[기재정정]단일판매ㆍ공급계약체결
Korean 12.5 KB
2025-07-14 00:00
전환주식의전환가액조정 (전환우선주)
Korean 11.3 KB
2025-05-22 00:00
주식등의대량보유상황보고서(약식)
Korean 79.7 KB
2025-05-21 00:00
[기재정정]투자판단관련주요경영사항 (CART 세포치료제 `AT101` 기술이전 계약 체결)
Korean 18.3 KB
2025-05-20 00:00
단일판매ㆍ공급계약체결
Korean 9.3 KB
2025-05-19 00:00
증권발행결과(자율공시)
Korean 6.1 KB
2025-05-19 00:00
전환주식의전환가액조정
Korean 12.0 KB
2025-05-15 00:00
단일판매ㆍ공급계약체결
Korean 9.4 KB
2025-05-15 00:00
분기보고서 (2025.03)
Korean 895.6 KB
2025-05-09 00:00
주요사항보고서(유상증자결정)
Korean 42.1 KB
2025-05-09 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 45.1 KB
2025-04-28 00:00
[기재정정]감사보고서제출
Korean 29.9 KB
2025-04-28 00:00
[기재정정]사업보고서 (2023.12)
Korean 522.3 KB

Automate Your Workflow. Get a real-time feed of all AbClon Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AbClon Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AbClon Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
ABEONA THERAPEUTICS INC. Logo
A clinical-stage biopharma developing cell and gene therapies for rare diseases.
United States of America
ABEO

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.